E Stefanich
Overview
Explore the profile of E Stefanich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coffey G, Stefanich E, Palmieri S, Eckert R, Padilla-Eagar J, Fielder P, et al.
J Pharmacol Exp Ther
. 2004 Jun;
310(3):896-904.
PMID: 15190122
Efalizumab (Raptiva) is a humanized CD11a-specific monoclonal antibody that was recently approved for the treatment of moderate to severe psoriasis. In psoriasis patients, the rate of efalizumab clearance from serum...
2.
Luoh S, Stefanich E, Solar G, Steinmetz H, Lipari T, Pestina T, et al.
Mol Cell Biol
. 1999 Dec;
20(2):507-15.
PMID: 10611229
The cytokine thrombopoietin (TPO) controls the formation of megakaryocytes and platelets from hematopoietic stem cells. TPO exerts its effect through activation of the c-Mpl receptor and of multiple downstream signal...
3.
Stefanich E, Senn T, Widmer R, Fratino C, Keller G, Fielder P
Blood
. 1997 Jun;
89(11):4063-70.
PMID: 9166846
Previous in vivo studies have established that plasma thrombopoietin (TPO) levels are regulated by binding to c-Mpl on platelets and that, in vitro, platelets bind and degrade TPO. To determine...
4.
Fielder P, Hass P, Nagel M, Stefanich E, Widmer R, Bennett G, et al.
Blood
. 1997 Apr;
89(8):2782-8.
PMID: 9108396
Recent studies have shown that plasma thrombopoietin (TPO) levels appear to be directly regulated by platelet mass and that removal of plasma TPO by platelets via binding to the c-Mpl...
5.
Fielder P, Gurney A, Stefanich E, Marian M, Moore M, de Sauvage F
Blood
. 1996 Mar;
87(6):2154-61.
PMID: 8630374
The involvement of platelets and the c-mpl receptor in the regulation of thrombopoietin (TPO) plasma concentrations and tissue mRNA levels was investigated in both normal mice and mice defective in...
6.
Watson N, Reddy H, Stefanich E, Eglen R
Eur J Pharmacol
. 1995 Oct;
285(2):135-42.
PMID: 8566131
The interaction of zamifenacin ((3R)-(+)-diphenylmethoxy-1-(3,4)-methylenedioxyphenethyl)pi peridine) at muscarinic receptor subtypes was studied using radioligand binding and functional techniques, in vitro. In radioligand binding studies, zamifenacin acted as a competitive antagonist,...
7.
Bonhaus D, Stefanich E, Loury D, Hsu S, Eglen R, Wong E
J Neurochem
. 1995 Jul;
65(1):104-10.
PMID: 7790853
Cooperation in the action of agonists suggests that there are multiple binding sites on 5-hydroxytryptamine3 (5-HT3) receptors. The purpose of this study was to characterize these binding sites and their...
8.
Tsou A, Kosaka A, Bach C, Zuppan P, Yee C, Tom L, et al.
J Neurochem
. 1994 Aug;
63(2):456-64.
PMID: 7518496
A cDNA clone (designated as GP2-7) encoding a novel 5-hydroxytryptamine (5-HT) receptor was isolated from a guinea pig hippocampal library. The receptor shares amino acid homology within the hydrophobic domains...
9.
Bonhaus D, Wong E, Stefanich E, Kunysz E, Eglen R
J Neurochem
. 1993 Nov;
61(5):1927-32.
PMID: 8229003
Previous studies have demonstrated species-specific differences in 5-hydroxytryptamine3 (5-HT3) receptors, but unequivocal evidence of 5-HT3 receptor subtypes, within a species, has not yet been obtained. The purpose of the current...
10.
Wong E, Bonhaus D, Wu I, Stefanich E, Eglen R
J Neurochem
. 1993 Mar;
60(3):921-30.
PMID: 8436978
RS-42358-197[(S)-N-(1-azabicyclo[2.2.2]oct-3-yl)-2,4,5,6-tetrahydro-1 H-benzo[de]isoquinolin-1-one hydrochloride] displaced the prototypic 5-hydroxytryptamine3 (5-HT3) receptor ligand [3H]quipazine in rat cerebral cortical membranes with an affinity (pKi) of 9.8 +/- 0.1, while having weak affinity (pKi <...